Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 5:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: RISPERDAL CONSTA Clear all
Completed Phase 4 Interventional Results available

Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder

NCT00423878
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Risperidone, Olanzapine, Quetiapine, Aripiprazole
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
28
States / cities
Colton, California • Palo Alto, California • New Haven, Connecticut + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 16, 2026, 5:56 PM EDT
Terminated Phase 4 Interventional Results available

Antipsychotic Effects on Brain Function in Schizophrenia

NCT01913327
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
Aripiprazole, Risperidone, Modafinil
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 40 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2020 · Synced Sep 16, 2026, 5:56 PM EDT
Completed No phase listed Observational

Long-term Antipsychotic Pediatric Safety Trial

NCT03522168
View directory record Official record
Conditions
Weight, Body
Interventions
Risperidone, Aripiprazole
Drug
Lead sponsor
Duke University
Other
Eligibility
3 Years to 18 Years
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
37
States / cities
Dothan, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 16, 2026, 5:56 PM EDT
Completed Not applicable Interventional Results available

First Episode Schizophrenia and Cannabis-Related Disorder Study

NCT00573287
View directory record Official record
Conditions
Cannabis-Related Disorder, Substance-Related Disorders, Schizophrenia, Psychotic Disorders
Interventions
clozapine, risperidone
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
17 Years to 45 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
5
States / cities
Concord, New Hampshire • Lebanon, New Hampshire • Manchester, New Hampshire + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Sep 16, 2026, 5:56 PM EDT
Completed Phase 3 Interventional Results available

Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients

NCT02109562
View directory record Official record
Conditions
Schizophrenia
Interventions
RBP-7000, Placebo, Risperidone
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
32
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Cerritos, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Sep 16, 2026, 5:56 PM EDT
Completed Phase 1 Interventional

Comparative Bioavailability of Risperidone.

NCT05179525
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone ISM® 100 mg, Risperdal 4mg Tablet
Drug
Lead sponsor
Rovi Pharmaceuticals Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
4
States / cities
Garden Grove, California • Gaithersburg, Maryland • Berlin, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Sep 16, 2026, 5:56 PM EDT
Terminated Phase 4 Interventional Results available

1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain

NCT01844700
View directory record Official record
Conditions
High Risk MC4R Genotype, Low Risk MC4R Genotype, One Week or Less Antipsychotic Lifetime Exposure
Interventions
Ziprasidone, aripiprazole, quetiapine, or risperidone
Drug
Lead sponsor
Northwell Health
Other
Eligibility
13 Years to 18 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Sep 16, 2026, 5:56 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia

NCT00333177
View directory record Official record
Conditions
Schizophrenia
Interventions
Cognitive remediation training (CT), Healthy behavior training (HBT), Risperidone, administered orally (Oral Ris), Risperidone, administered via injection (RLAI)
Behavioral · Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Sep 16, 2026, 5:56 PM EDT
Completed Phase 4 Interventional Results available

Treatment of Severe Childhood Aggression (The TOSCA Study)

NCT00796302
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate HCl, Risperidone, Parent Management Training (PMT), Placebo
Drug · Behavioral
Lead sponsor
Michael Aman
Other
Eligibility
6 Years to 12 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
Stony Brook, New York • Cleveland, Ohio • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Sep 16, 2026, 5:56 PM EDT
Completed Phase 4 Interventional Results available

Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy

NCT00330863
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Risperidone microspheres, Risperidone, Olanzapine, Quetiapine, Ziprasidone, Aripiprazole, Paliperidone
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 65 Years
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
8
States / cities
Los Angeles, California • Augusta, Georgia • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Sep 16, 2026, 5:56 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism

NCT02237417
View directory record Official record
Conditions
Schizophrenia
Interventions
Standard of Care Oral antipsychotics, IM aripiprazole once monthly, No Treatment
Drug · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 35 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Sep 16, 2026, 5:56 PM EDT
Completed Phase 4 Interventional Results available

A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder

NCT00206102
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
quetiapine fumarate, risperidone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,098 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
63
States / cities
Little Rock, Arkansas • Mabelvale, Arkansas • Morrilton, Arkansas + 60 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2013 · Synced Sep 16, 2026, 5:56 PM EDT
Completed Phase 2 Interventional

A Comparator Study of LY2140023 Versus Placebo in Schizophrenia Patients

NCT01086748
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone, Placebo, LY2140023
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
19
States / cities
Escondido, California • Garden Grove, California • Paramount, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 16, 2026, 5:56 PM EDT
Completed Phase 4 Interventional

Janssen Asperger's MRS (Magnetic Resonance Spectroscopy Risperidone Study

NCT00352196
View directory record Official record
Conditions
Asperger's Disorder
Interventions
Risperidone, Magnetic Resonance Spectroscopy
Drug · Other
Lead sponsor
Augusta University
Other
Eligibility
6 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 13, 2015 · Synced Sep 16, 2026, 5:56 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Reducing the Abuse Liability of Prescription Opioids

NCT04587115
View directory record Official record
Conditions
Addiction
Interventions
Risperidone, Ziprasidone, Oxycodone
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
21 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2020 · Synced Sep 16, 2026, 5:56 PM EDT
Completed Phase 3 Interventional Results available

Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents

NCT00057681
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium carbonate, Valproate, Risperidone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
6 Years to 15 Years
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2013 · Synced Sep 16, 2026, 5:56 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Pharmacogenomics in Autism Treatment

NCT00584701
View directory record Official record
Conditions
Autism
Interventions
Risperidone
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
4 Years to 18 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2012 · Synced Sep 16, 2026, 5:56 PM EDT
Completed Phase 4 Interventional Results available

A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa

NCT00140426
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
Risperidone, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 21 Years · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 1, 2016 · Synced Sep 16, 2026, 5:56 PM EDT
Completed Phase 1 Interventional

Bioavailability of LY03004 and Risperdal® Consta®

NCT02091388
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
LY03004, Risperdal® Consta®
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
10
States / cities
Little Rock, Arkansas • Long Beach, California • Orange, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2015 · Synced Sep 16, 2026, 5:56 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia

NCT00694707
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, Cariprazine, Risperidone
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 60 Years
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
18
States / cities
Costa Mesa, California • Long Beach, California • Oceanside, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Sep 16, 2026, 5:56 PM EDT
Completed Phase 3 Interventional

Effects of Risperdal Consta on Ability to Benefit From Social Skills Training in Schizophrenia

NCT00148083
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Risperdal Consta (drug), Social Skills Training
Drug · Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 55 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Chicago, Illinois • White Plains, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Sep 16, 2026, 5:56 PM EDT
Terminated Phase 4 Interventional

Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal

NCT00314613
View directory record Official record
Conditions
Schizophrenia
Interventions
Antipsychotic/Risperidone Consta
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 40 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
Butner, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 1, 2017 · Synced Sep 16, 2026, 5:56 PM EDT
Completed No phase listed Observational

Cross-Sectional Iloperidone IVGTT

NCT01686815
View directory record Official record
Conditions
Schizophrenia, Serious Mental Illness, Metabolic Syndrome, Insulin Resistance, Glucose Metabolism
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 11, 2019 · Synced Sep 16, 2026, 5:56 PM EDT
Completed Phase 4 Interventional Results available

15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated

NCT01157351
View directory record Official record
Conditions
Schizophrenia
Interventions
paliperidone, risperidone, haloperidole, perphenazine, aripiprazole, quetiapine, paliperidone palmitate, olanzapine
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
55
States / cities
Bullhead City, Arizona • Tuscon, Arizona • Little Rock, Arkansas + 52 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Sep 16, 2026, 5:56 PM EDT